CAI vs LEN · rev $216.8M vs rev $34.19B
Caris Life Sciences, Inc. Common Stock (CAI) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
LEN (LEN) common stock.
Latest reported CAI revenue for 2025-09-30 was $216.8M. Net income was $24.3M. Revenue was up 19.5% from 2025-06-30 to 2025-09-30. CAI currently screens at market cap $5.22B.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
CAI currently screens at market cap $5.22B. LEN currently screens at market cap $0.
Not investment advice. Open the CAI and LEN stock pages for the full models.
Not investment advice.